|
1
|
Grunstein M: Histone acetylation in
chromatin structure and transcription. Nature. 389:349–352. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glass CK and Rosenfeld MG: The coregulator
exchange in transcriptional functions of nuclear receptors. Genes
Dev. 14:121–141. 2000.PubMed/NCBI
|
|
3
|
Grignani F, De Matteis S, Nervi C,
Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara
FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci
PG: Fusion proteins of the retinoic acid receptor-α recruit histone
deacetylase in promyelocytic leukaemia. Nature. 391:815–818.
1998.
|
|
4
|
Garcia-Manero G, Yang H, Bueso-Ramos C, et
al: Phase 1 study of the histone deacetylase inhibitor vorinostat
(suberoylanilide hydroxamic acid [SAHA]) in patients with advanced
leukemias and myelodysplastic syndromes. Blood. 111:1060–1066.
2008.
|
|
5
|
Blumenschein GR Jr, Kies MS,
Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C
and Frankel SR: Phase II trial of the histone deacetylase inhibitor
(Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with
recurrent and/or metastatic head and neck cancer. Invest New Drugs.
26:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qian DZ, Kato Y, Shabbeer S, Wei Y,
Verheul HM, Salumbides B, Sanni T, Atadja P and Pili R: Targeting
tumor angiogenesis with histone deacetylase inhibitors: the
hydroxamic acid derivative LBH589. Clin Cancer Res. 12:634–642.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertino E and Otterson GA: Romidepsin: a
novel histone deacetylase inhibitor for cancer. Expert Opin
Investig Drugs. 20:1151–1158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramalingam SS, Kummar S, Sarantopoulos J,
Shibata S, Lo Russo P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey
RD, Ivy SP, Belani CP and Egorin MJ: Phase I study of vorinostat in
patients with advanced solid tumors and hepatic dysfunction: a
National Cancer Institute Organ Dysfunction Working Group study. J
Clin Oncol. 28:4507–4512. 2010. View Article : Google Scholar
|
|
10
|
Butler LM, Zhou X, Xu WS, Scher HI,
Rifkind RA, Marks PA and Richon VM: The histone deacetylase
inhibitor SAHA arrests cancer cell growth, up-regulates
thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc
Natl Acad Sci USA. 99:11700–11705. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen LA, Marks PA, Rifkind RA, Amin S,
Desai D, Pittman B and Richon VM: Suberoylanilide hydroxamic acid
(SAHA), a histone deacetylase inhibitor, suppresses the growth of
carcinogen-induced mammary tumors. Anticancer Res. 22:1497–1504.
2002.PubMed/NCBI
|
|
12
|
Nakata S, Yoshida T, Horinaka M, Shiraishi
T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate
death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/
APO2-L in human malignant tumor cells. Oncogene. 23:6261–6271.
2004. View Article : Google Scholar
|
|
13
|
Guo F, Sigua C, Tao J, Bali P, George P,
Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K: Cotreatment
with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor
necrosis factor-related apoptosis inducing ligand-induced death
inducing signaling complex activity and apoptosis of human acute
leukemia cells. Cancer Res. 64:2580–2589. 2004. View Article : Google Scholar
|
|
14
|
Kim MS, Blake M, Baek JH, Kohlhagen G,
Pommier Y and Carrier F: Inhibition of histone deacetylase
increases cytotoxicity to anticancer drugs targeting DNA. Cancer
Res. 63:7291–7300. 2003.PubMed/NCBI
|
|
15
|
Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY,
Bang YJ and Lee JS: The histone deacetylase inhibitor trichostatin
A sensitizes estrogen receptor α-negative breast cancer cells to
tamoxifen. Oncogene. 23:1724–1736. 2004.PubMed/NCBI
|
|
16
|
Licznar A, Caporali S, Lucas A, Weisz A,
Vignon F and Lazennec G: Identification of genes involved in growth
inhibition of breast cancer cells transduced with estrogen
receptor. FEBS Lett. 553:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Srivastava RK, Kurzrock R and Shankar S:
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits
angiogenesis and metastasis and reverses epithelial-mesenchymal
transition in vivo. Mol Cancer Ther. 9:3254–3266. 2010. View Article : Google Scholar
|
|
18
|
Page B, Page M and Noel C: A new
fluorimetric assay for cytotoxicity measurements in vitro. Int J
Oncol. 3:473–476. 1993.PubMed/NCBI
|
|
19
|
Workman P, Aboagye EO, Balkwill F, et al:
Guidelines for the welfare and use of animals in cancer research.
Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Plowman J, Dykes DJ, Melinda H,
Simpson-Hellen L and Alley MC: Human tumor xenograft models in NCI
drug development. Anticancer Drug Development Guide. Teicher BA:
Humana Press; Totowa, NJ: pp. 101–126. 1997, View Article : Google Scholar
|
|
21
|
Koopman G, Reutelingsperger CP, Kuijten
GA, Keehnen RM, Pals ST and van Oers MH: Annexin V for flow
cytometric detection of phosphatidylserine expression on B cells
undergoing apoptosis. Blood. 84:1415–1420. 1994.PubMed/NCBI
|
|
22
|
Livak KJ: ABI Prism 7700 Sequence
Detection System. User Bulletin No. 2. PE Applied Biosystems AB
website, Bulletin Reference 4303859B 77802-002,. 1997.
|
|
23
|
Archer SY, Johnson J, Kim HJ, Ma Q, Mou H,
Daesety V, Meng S and Hodin RA: The histone deacetylase inhibitor
butyrate downregulates cyclin B1 gene expression via a p21/
WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol
Gastrointest Liver Physiol. 289:G696–G703. 2005.
|
|
24
|
Hellebrekers DM, Melotte V, Viré E,
Langenkamp E, Molema G, Fuks F, Herman JG, van Criekinge W,
Griffioen AW and van Engeland M: Identification of epigenetically
silenced genes in tumor endothelial cells. Cancer Res.
67:4138–4148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim HR, Kim E-J, Yang S-H, Jeong E-T, Park
C, Lee J-H, Youn M-J, So H-S and Park R: Trichostatin A induces
apoptosis in lung cancer cells via simultaneous activation of the
death receptor-mediated and mitochondrial pathway. Exp Mol Med.
38:616–624. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shankar S, Davis R, Singh KP, Kurzrock R,
Ross DD and Srivastava RK: Suberoylanilide hydroxamic acid
(Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells
orthotopically implanted in BALB/c nude mice. Mol Cancer Ther.
8:1596–1605. 2009. View Article : Google Scholar
|
|
27
|
Vire B, De Walque S, Restouin A, Olive D,
van Lint C and Collette Y: Anti-leukemia activity of MS-275 histone
deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory
functions. PLoS One. 4:e70852009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Y, Chen JH and Fu Y: Immunotherapy
with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol.
1:31–36. 2004.PubMed/NCBI
|
|
29
|
Shao Z and Schwarz H: CD137 ligand, a
member of the tumor necrosis factor family, regulates immune
responses via reverse signal transduction. J Leukoc Biol. 89:21–29.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gullo C, Koh LK, Pang WL, Ho KT, Tan SH
and Schwarz H: Inhibition of proliferation and induction of
apoptosis in multiple myeloma cell lines by CD137 ligand signaling.
PLoS One. 5:e108452010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tai YT, Catley LP, Mitsiades CS, Burger R,
Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M,
Ishitsuka K, Richardson P, Treon SP, Munshi NC and Anderson KC:
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces
cytotoxicity in human multiple myeloma cells: clinical
implications. Cancer Res. 64:2846–2852. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu SE, Park SH and Jang YK: Epigenetic
silencing of TNFSF7 (CD70) by DNA methylation during progression to
breast cancer. Mol Cells. 29:217–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dimberg J, Hugander A and Wagsater D:
Expression of CD137 and CD137L in colorectal cancer patients. Oncol
Rep. 15:1197–1200. 2006.PubMed/NCBI
|
|
34
|
Nicolin V and Narducci P: Soluble TRAIL
could enhance bone destruction acting on Rank-ligand in
estrogen-independent human breast cancer cell line MDA-MB-231. Acta
Histochem. 112:1189–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
